The content on this site is intended for healthcare professionals only
Dr Paolo Ghia presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the ASCEND study.
Patients with relapsed or refractory chronic lymphocytic leukaemia were randomised to receive either acalabrutinib or the investigator choice of rituximab plus idelalisib (IdR) with acalabrutinib showing a much improved PFS and safety profile.
Understanding the remaining unmet needs in a post ASCT NDMM setting
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ASCO 2024: Lung cancer highlights
EHA 2024: Multiple myeloma roundup
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Updates on lung cancer from WCLC and ESMO 2023
Efficacy and safety of belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma
